Zoetis Inc. (NYSE:ZTS) Shares Acquired by Dupont Capital Management Corp

Dupont Capital Management Corp increased its position in Zoetis Inc. (NYSE:ZTS) by 28.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,190 shares of the company’s stock after acquiring an additional 8,596 shares during the period. Dupont Capital Management Corp’s holdings in Zoetis were worth $7,657,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Asset Dedication LLC grew its holdings in Zoetis by 4.8% during the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after buying an additional 54 shares during the last quarter. Forza Wealth Management LLC grew its holdings in Zoetis by 1.8% during the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after buying an additional 58 shares during the last quarter. L. Roy Papp & Associates LLP grew its holdings in Zoetis by 2.8% during the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after buying an additional 60 shares during the last quarter. Grove Bank & Trust grew its holdings in Zoetis by 0.5% during the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock valued at $2,298,000 after buying an additional 61 shares during the last quarter. Finally, Angeles Wealth Management LLC grew its holdings in Zoetis by 3.8% during the 1st quarter. Angeles Wealth Management LLC now owns 1,702 shares of the company’s stock valued at $288,000 after buying an additional 62 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.0 %

Shares of ZTS opened at $189.52 on Wednesday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $86.48 billion, a P/E ratio of 36.52, a price-to-earnings-growth ratio of 3.00 and a beta of 0.89. The stock’s fifty day simple moving average is $189.11 and its 200 day simple moving average is $177.50. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the company posted $1.41 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.14%.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus raised their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.